The FDA's big gamble on the new Alzheimer's drug
- Written by C. Michael White, Distinguished Professor and Head of the Department of Pharmacy Practice, University of Connecticut
Do the benefits of approving a drug before confirming it works outweigh the potential costs?monkeybusinessimages/iStock via Getty Images PlusThe Food and Drug Administration set off a firestorm of debate when it approved a new drug, aducanumab, for Alzheimer’s disease via an accelerated approval pathway. This decision ignored the...